BOSTON (Thomson Financial) - Bayer AG's Bayer HealthCare Wednesday said has agreed to acquire Maxygen Inc.'s hemophilia program assets for $90 million with a final, potential milestone payment of $30 million. The agreement includes a next-generation recombinant Factor VIIa protein, known as MAXY-VII, and a license to use Maxygen's molecular breeding technology for exploiting gene targets. Bayer HealthCare said the agreement fits into its growth strategy for its specialty pharmaceutical business.
One more pharma/biotech acquisition. BD
stocks, shares, news, FTSE, online trading - Interactive Investor